Opinion: Health Booth 2020

Using a SMART card containing your genetic information and medical history, you could one day soon be diagnosed and treated for all kinds of diseases at an ATM-style kiosk.

Written byPushkar N. Kaul
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

WIKIMEDIA, WALTER BAXTERFrance was the first country to use plastic-embedded simultaneous multiple algorithm technology (SMART) back in early 1970s. We then witnessed a global explosion of these data-holding cards for banking and other applications during the following decades. Now, at the start of this century, we are pushing this technology into health care by beginning to develop a health SMART (H-SMART) card that has the potential to transform health care delivery into a more efficient, precise, economic, and readily accessible system than ever before imaginable.

The development of the H-SMART card also began in France, starting out in the 1990s as a health insurance card and later, when a federal law was passed in 2004, came to include an individual’s medical history. Germany introduced a similar health insurance card in the early 2000s, and last October added the medical history element. Soon, both these countries will require their citizens to have an H-SMART card to obtain health care and insurance.

It is expected that the European H-card will be developed to include a comprehensive health history in the next few years. And in the next decade or so, the card will likely be updated to include an individual’s genetic information as well. Thus, the H-SMART card eventually will contain a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies